SCHEDULE 13G/A: UBS Group AG Amends Schedule 13G Filing for Renalytix plc, Correcting Event Date

UBS Group AG has filed an amendment to its Schedule 13G for Renalytix plc, primarily to correct the 'Date of Event Which Requires Filing of this Statement' to March 31, 2025.

Summary

• UBS Group AG filed an Amendment No. 2 to its Schedule 13G regarding its beneficial ownership of Ordinary shares of Renalytix plc.
• The primary purpose of this amendment is to correct the 'Date of Event Which Requires Filing of this Statement' from April 30, 2025, to the correct date of March 31, 2025.
• UBS Group AG, a Swiss entity, reported 0.00 shares beneficially owned in Renalytix plc, representing 0.0% of the class.
• The filing indicates that UBS Group AG, as a parent holding company, is filing on behalf of itself and its wholly-owned subsidiary, UBS AG London Branch.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Renalytix plc.

Sentiment

Score: 5

Explanation: The document is neutral as it is a routine administrative amendment to correct a date on a beneficial ownership filing where the reported ownership is 0%. It contains no new material information regarding the issuer's operations or financial health.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding Renalytix plc's future performance or operations.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing is a routine regulatory disclosure by a financial institution (UBS Group AG) regarding its minimal (0%) beneficial ownership in a publicly traded company (Renalytix plc). It does not reflect broader industry trends or competitive dynamics, but rather compliance with SEC reporting requirements for institutional investors.

Stakeholder Impact

• Shareholders: Minimal to no direct impact, as the filing confirms 0% beneficial ownership by UBS Group AG and is an administrative correction.
• Employees, Customers, Suppliers, Creditors: No direct impact from this administrative filing.

Key Dates

Keywords

Renalytix plc, UBS Group AG, Schedule 13G, Beneficial Ownership, SEC Filing, Ordinary Shares, Amendment